Literature DB >> 24255133

Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

Carla Giordano1, Valentina Guarnotta, Rosario Pivonello, Marco Calogero Amato, Chiara Simeoli, Alessandro Ciresi, Alessia Cozzolino, Annamaria Colao.   

Abstract

OBJECTIVE: Diabetes mellitus (DM) is one of the most frequent complications of Cushing's syndrome (CS). The aim of this study was to define the changes in insulin sensitivity and/or secretion in relation to glucose tolerance categories in newly diagnosed CS patients.
DESIGN: Cross-sectional study on 140 patients with CS.
METHODS: A total of 113 women (80 with pituitary disease and 33 with adrenal disease, aged 41.7±15.7 years) and 27 men (19 with pituitary disease and eight with adrenal disease, aged 38.1±20.01 years) at diagnosis were divided according to glucose tolerance into normal glucose tolerance (CS/NGT), impaired fasting glucose and/or impaired glucose tolerance (CS/prediabetes), and diabetes (CS/DM) groups.
RESULTS: Seventy-one patients had CS/NGT (49.3%), 26 (18.5%) had CS/prediabetes and 43 (30.8%) had CS/DM. Significant increasing trends in the prevalence of family history of diabetes (P<0.001), metabolic syndrome (P<0.001), age (P<0.001) and waist circumference (P=0.043) and decreasing trends in HOMA-β (P<0.001) and oral disposition index (DIo) (P<0.002) were observed among the groups. No significant trends in fasting insulin levels, area under the curve for insulin (AUCINS), Matsuda index of insulin sensitivity (ISI-Matsuda) and visceral adiposity index were detected.
CONCLUSIONS: Impairment of glucose tolerance is characterized by the inability of β-cells to adequately compensate for insulin resistance through increased insulin secretion. Age, genetic predisposition and lifestyle, in combination with the duration and degree of hypercortisolism, strongly contribute to the impairment of glucose tolerance in patients with a natural history of CS. A careful phenotypic evaluation of glucose tolerance defects in patients with CS proves useful for the identification of those at a high risk of metabolic complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24255133     DOI: 10.1530/EJE-13-0754

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  27 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease.

Authors:  Valentina Guarnotta; Alessandro Ciresi; Maria Pitrone; Giuseppe Pizzolanti; Carla Giordano
Journal:  Endocrine       Date:  2017-03-17       Impact factor: 3.633

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Glucose metabolism in Cushing's syndrome.

Authors:  Anu Sharma; Adrian Vella
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

5.  The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome.

Authors:  Valentina Guarnotta; Marco C Amato; Rosario Pivonello; Giorgio Arnaldi; Alessandro Ciresi; Laura Trementino; Roberto Citarrella; Davide Iacuaniello; Grazia Michetti; Chiara Simeoli; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2016-03-10       Impact factor: 3.633

Review 6.  Clinical and biochemical manifestations of Cushing's.

Authors:  Georgia Ntali; Ashley Grossman; Niki Karavitaki
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

7.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

8.  Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study.

Authors:  A Albani; F Ferraù; A Ciresi; R Pivonello; C Scaroni; D Iacuaniello; M Zilio; V Guarnotta; A Alibrandi; E Messina; M Boscaro; C Giordano; A Colao; S Cannavo
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

9.  Gender-Specific Differences in Clinical Profile and Biochemical Parameters in Patients with Cushing's Disease: A Single Center Experience.

Authors:  Xiaoxia Liu; Xiaoming Zhu; Meifang Zeng; Yan Zhuang; Yiting Zhou; Zhaoyun Zhang; Yehong Yang; Yongfei Wang; Hongying Ye; Yiming Li
Journal:  Int J Endocrinol       Date:  2015-05-06       Impact factor: 3.257

Review 10.  Visceral adiposity index: an indicator of adipose tissue dysfunction.

Authors:  Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2014-04-14       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.